Clinical trials: Pancreatic Cancer Stage
Cancer, PDAC - Pancreatic Ductal Adenocarcinoma
A Study to Learn About Study Medicine ALTA3263 in Adults With Advanced Solid Tumors With KRAS Mutations
The purpose of this study is to characterize the safety and tolerability of ALTA3263 in adults with advanced solid tumors with KRAS mutations.
- Conditions
- Cancer, PDAC - Pancreatic Ductal Adenocarcinoma, NSCLC (Non-small Cell Lung Cancer), CRC (Colorectal Cancer)
- Trial name
- NCT06835569
- Testing
- ALTA3263, cetuximab, mFOLFOX6
- Where
- 14 sites in United States
- Volunteers
- 448 people
- Sponsor
- Alterome Therapeutics, Inc.
Neoplasms Pancreatic
PRIMUS 001: A Study Looking at Two Different Chemotherapy Regimens in Patients With Metastatic Pancreatic Cancer
This study is comparing two combinations of chemotherapy treatments in patients with metastatic pancreatic cancer. Half the participants will receive FOLFOX-A and the other half will receive AG.
- Trial name
- NCT04151277
- Testing
- FOLFOX-A, Gemcitabe and Abraxane, G-CSF
- Where
- 30 sites in United Kingdom
- Volunteers
- 500 people
- Sponsor
- Judith Dixon-Hughes
Metastatic Pancreatic Adenocarcinoma, Stage IV Pancreatic Cancer AJCC v8
Pembrolizumab and PEGPH20 in Treating Patients With Metastatic Pancreatic Cancer
This phase II trial studies how well pembrolizumab and PEGPH20 work in treating patients with pancreatic cancer that has spread to other places in the body (metastatic).
- Trial name
- NCT04058964
- Testing
- Pegylated Recombinant Human Hyaluronidase PH20, Pembrolizumab
- Where
- United States
- Sponsor
- M.D. Anderson Cancer Center
Pancreas Cancer, Relapse
Autologous CAR-T Cells Targeting B7-H3 in PDAC
The purpose of this gene therapy research study is to test the safety and tolerability of using a new treatment called autologous T lymphocyte chimeric antigen receptor cells against the B7-H3 antigen (iC9.CAR.B7-H3 T cells) in…
- Conditions
- Pancreas Cancer, Relapse, Resistant Cancer
- Trial name
- NCT06158139
- Testing
- iC9-CAR.B7-H3 T cell infusion
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Resectable Pancreatic Body/Tail Carcinoma
Isolation Procedure vs. Conventional Procedure During Distal Pancreatectosplenectomy for Pancreatic Cancer
In the distal pancreatectomy (including pancreatic tail resection) for invasive ductal carcinoma of the pancreas, we evaluate the usefulness of a procedure of firstly transection of splenic arteries and veins (the isolation…
- Trial name
- ISOP-DP (NCT04600063)
- Testing
- Isolation procedure (RAMPS procedure), Conventional procedure
- Where
- 10 sites in Japan
- Volunteers
- 100 people
- Sponsor
- Wakayama Medical University
Metastatic Pancreatic Cancer, Colorectal Cancer
A Study to Evaluate the Safety, Tolerability, and Activity of TAK-931 in Participants With Metastatic Pancreatic Cancer, Metastatic Colorectal Cancer, and Other Advanced Solid Tumors
The purpose of this study is to confirm the safety and tolerability of TAK-931 in a cohort of Western participants with metastatic solid tumors and to evaluate the anti-tumor activity of TAK-931 in participants with metastatic…
- Conditions
- Metastatic Pancreatic Cancer, Colorectal Cancer, Esophageal Neoplasms, Carcinoma, Non-small-cell Lung
- Trial name
- NCT03261947
- Testing
- TAK-931
- Where
- 10 sites in United States, Japan
- Volunteers
- 101 people
- Sponsor
- Millennium Pharmaceuticals, Inc.
Pancreatic Cancer
Gemcitabine, Capecitabine, and Bevacizumab in Treating Patients With Metastatic or Unresectable Pancreatic Cancer
RATIONALE: Drugs used in chemotherapy, such as gemcitabine and capecitabine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00100815
- Testing
- bevacizumab, capecitabine, gemcitabine hydrochloride
- Where
- 2 sites in United States
- Volunteers
- 50 people
- Sponsor
- Roswell Park Cancer Institute
Gastro-entero-pancreatic Carcinoma, Esophageal Neuroendocrine Carcinoma
Octreotide LAR as Maintenance Treatment for Patients With NEC
This is phase II study on the efficacy of octreotide lar as maintenance treatment after first-line chemotherapy for patients with unresectable or metastatic gastro-entero-pancreatic or esophageal neuroendocrine carcinomas.
- Trial name
- NCT02409849
- Testing
- Octreotide lar
- Where
- China
- Volunteers
- 92 people
- Sponsor
- Peking University
Pancreatic Neoplasms
Aroplatin and Gemcitabine in Patients With Advanced Pancreatic Cancer Resistant to Standard Therapies
This study is a Phase I/II study. In Phase I of this study, the objective is to determine the maximum tolerated dose (MTD) of combination therapy with Aroplatin and gemcitabine (Gemzar®) in subjects with unresectable, locally…
- Trial name
- NCT00081549
- Testing
- Aroplatin (Liposomal NDDP, L-NDDP)
- Volunteers
- 111 people
- Sponsor
- Aronex Pharmaceuticals
Pancreatic Cancer
Neoadjuvant Accelerated Short Course Radiation Therapy With Photons and Capecitabine for Resectable Pancreatic Cancer
The purpose of this research study is to determine if it is possible to deliver high dose radiation in one week while also giving the drug capecitabine for the treatment of pancreatic cancer prior to surgery, to determine if this…
- Trial name
- NCT00889187
- Testing
- Neoadjuvant Short-Course Photon Radiation, Capecitabine
- Where
- 3 sites in United States
- Volunteers
- 10 people
- Sponsor
- Dana-Farber Cancer Institute
Peritoneal Carcinomatosis, Peritoneal Metastases
Intraperitoneal Aerosolized Nanoliposomal Irinotecan (Nal-IRI) in Peritoneal Carcinomatosis From Gastrointestinal Cancer
The PIPAC NAL-IRI study is designed to examine the maximal tolerated dose of nanoliposomal irinotecan (Nal-IRI, Onivyde) administered with repeated pressurized intraperitoneal aerosol chemotherapy (PIPAC), in a monocentric, phase…
- Conditions
- Peritoneal Carcinomatosis, Peritoneal Metastases, Colorectal Cancer, Small Bowel Cancer
- Trial name
- PIPAC-NAL-IRI (NCT05277766)
- Testing
- PIPAC with Nal-IRI
- Where
- Belgium
- Volunteers
- 45 people
- Sponsor
- University Hospital, Ghent
Pancreas Cancer
Intraoperative Radiation Therapy for Resectable Pancreas Cancer
Currently, for patients with pancreatic cancer the standard treatment is surgery followed by chemotherapy and/or radiation therapy.
- Trial name
- IORT (NCT02599662)
- Testing
- 10 Gy Low-KV IORT, 15 Gy Low-KV IORT, 20 GY Low-KV IORT
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Loyola University
Well-differentiated Non-functional NET of Thoracic Origin, Well-differentiated Non-functional NET of Gastrointestinal Origin
Study of Efficacy and Safety of PDR001 in Patients With Advanced or Metastatic, Well-differentiated, Non-functional Neuroendocrine Tumors of Pancreatic, Gastrointestinal (GI), or Thoracic Origin or Poorly-differentiated Gastroenteropancreatic Neuroendocrine Carcinoma (GEP-NEC)
This study aimed to investigate the efficacy and safety of PDR001 in patients with advanced or metastatic, well-differentiated, non-functional neuroendocrine tumors of pancreatic, gastrointestinal (GI), or thoracic origin or…
- Conditions
- Well-differentiated Non-functional NET of Thoracic Origin, Well-differentiated Non-functional NET of Gastrointestinal Origin, Well-differentiated Non-functional NET of Pancreatic Origin, Poorly-differentiated Gastroenteropancreatic Neuroendocrine Carcinoma
- Trial name
- NCT02955069
- Testing
- PDR001
- Where
- 35 sites in United States, Australia and 10 more
- Volunteers
- 116 people
- Sponsor
- Novartis Pharmaceuticals
Pancreatic Cancer
Vitamin E δ-Tocotrienol Multiple Dose in Healthy Subjects
The Principal Investigator believes that Vitamin E δ-Tocotrienol will slow the progression of pancreatic cancer cells. Therefore, the investigators must determine the safety and tolerability of Vitamin E δ-Tocotrienol in healthy…
- Trial name
- NCT01450046
- Testing
- Vitamin E δ-Tocotrienol
- Where
- United States
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Pancreatic Cancer
Cisplatin, Metronomic Low-Dose Interferon Alfa, Gemcitabine, and Fever-Range Whole-Body Hyperthermia in Treating Patients With Inoperable or Metastatic Pancreatic Cancer
RATIONALE: Drugs used in chemotherapy, such as cisplatin and gemcitabine, work in different ways to stop tumor cells from dividing so they stop growing or die.
- Trial name
- NCT00082862
- Testing
- recombinant interferon alfa, cisplatin, gemcitabine hydrochloride
- Where
- United States
- Volunteers
- 48 people
- Sponsor
- The University of Texas Health Science Center, Houston
Metastatic Cancer, Solid Tumor
LYT-200 Alone and in Combination With Chemotherapy or Tislelizumab in Patients With Locally Advanced or Metastatic Solid Tumors
A Phase 1/2 Open-label, Multi-center Study of the Safety, Pharmacokinetics, and Anti-tumor Activity of LYT-200 Alone and in Combination with Chemotherapy or Tislelizumab in Patients with Metastatic Solid Tumors
- Conditions
- Metastatic Cancer, Solid Tumor, Pancreatic Cancer, Urothelial Carcinoma
- Trial name
- NCT04666688
- Testing
- LYT-200, Tislelizumab, Gemcitabine/nab-paclitaxel
- Where
- 12 sites in United States
- Volunteers
- 44 people
- Sponsor
- PureTech
Metastatic Solid Tumors, Advanced Non-squamous Non-small-cell Lung Cancer
A First-in-human Study of BGB-53038, a Pan-KRAS Inhibitor, Alone or in Combinations in Participants With Advanced or Metastatic Solid Tumors With KRAS Mutations or Amplification
This is a first-in-human (FIH), open-label, multicenter, dose escalation and dose expansion study to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics, and preliminary antitumor activity of BGB-53038 as…
- Conditions
- Metastatic Solid Tumors, Advanced Non-squamous Non-small-cell Lung Cancer, Advanced Colorectal Cancer, Advanced Pancreatic Ductal Adenocarcinoma
- Trial name
- NCT06585488
- Testing
- BGB-53038, Tislelizumab, Cetuximab
- Where
- 17 sites in United States, Australia and 3 more
- Volunteers
- 47 people, healthy volunteers welcome
- Sponsor
- BeOne Medicines
Liver Cancer, Biliary Tract Cancer
Early-stage Detection of LIver, Biliary TRAct and PancReatic Cancers
LIBRARY is a prospective, multi-center, observational study aimed at detecting early liver, biliary tract, and pancreatic cancers by combining assays of cell-free DNA (cfDNA) methylation, serum protein, and microRNA.
- Conditions
- Liver Cancer, Biliary Tract Cancer, Pancreatic Cancer
- Trial name
- NCT06139042
- Testing
- Blood drawing
- Where
- China
- Volunteers
- 1,608 people, healthy volunteers welcome
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Advanced Solid Tumor, Non-small Cell Lung Cancers
Phase Ib Trial of the KRAS G12C Inhibitor Adagrasib (MRTX849) in Combination With the PARP Inhibitor Olaparib in Patients With KRAS G12C Mutated Advanced Solid Tumors, With a Focus on Gynecological, Breast, Pancreatic and KEAP1 Mutated Non-small Cell Lung Cancers
Evaluate safety and tolerability, while establishing the recommended dose of the investigational drug combination of adagrasib and olaparib that can be given to participants with advanced solid tumor(s) with a KRAS G12C and/or…
- Trial name
- NCT06130254
- Testing
- Adagrasib, Olaparib
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- M.D. Anderson Cancer Center
Pancreatic Cancer, Pancreatic Ductal Adenocarcinoma
Paclitaxel Protein Bound Plus Cisplatin Plus Gemcitabine and Paricalcitol for Pancreatic Adenocarcinoma (NABPLAGEMD)
The purpose of this study is to determine if the combination of paclitaxel protein bound, gemcitabine, cisplatin, paricalcitol are effective in individuals with previously untreated metastatic pancreatic cancer.
- Conditions
- Pancreatic Cancer, Pancreatic Ductal Adenocarcinoma, Pancreatic Adenocarcinoma, Pancreas Metastases
- Trial name
- NABPLAGEMD (NCT03415854)
- Testing
- Paricalcitol (Zemplar)
- Where
- United States
- Volunteers
- 34 people
- Sponsor
- HonorHealth Research Institute
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.